223 related articles for article (PubMed ID: 16338280)
1. CYP2C19 genotype affects diazepam pharmacokinetics and emergence from general anesthesia.
Inomata S; Nagashima A; Itagaki F; Homma M; Nishimura M; Osaka Y; Okuyama K; Tanaka E; Nakamura T; Kohda Y; Naito S; Miyabe M; Toyooka H
Clin Pharmacol Ther; 2005 Dec; 78(6):647-55. PubMed ID: 16338280
[TBL] [Abstract][Full Text] [Related]
2. Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status.
Kosuge K; Jun Y; Watanabe H; Kimura M; Nishimoto M; Ishizaki T; Ohashi K
Drug Metab Dispos; 2001 Oct; 29(10):1284-9. PubMed ID: 11560871
[TBL] [Abstract][Full Text] [Related]
3. Voriconazole and fluconazole increase the exposure to oral diazepam.
Saari TI; Laine K; Bertilsson L; Neuvonen PJ; Olkkola KT
Eur J Clin Pharmacol; 2007 Oct; 63(10):941-9. PubMed ID: 17676319
[TBL] [Abstract][Full Text] [Related]
4. Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics.
Gashaw I; Kirchheiner J; Goldammer M; Bauer S; Seidemann J; Zoller K; Mrozikiewicz PM; Roots I; Brockmöller J
Clin Pharmacol Ther; 2003 Nov; 74(5):448-57. PubMed ID: 14586385
[TBL] [Abstract][Full Text] [Related]
5. In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease.
Ohnishi A; Murakami S; Akizuki S; Mochizuki J; Echizen H; Takagi I
J Clin Pharmacol; 2005 Nov; 45(11):1221-9. PubMed ID: 16239354
[TBL] [Abstract][Full Text] [Related]
6. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans.
Furuta T; Ohashi K; Kobayashi K; Iida I; Yoshida H; Shirai N; Takashima M; Kosuge K; Hanai H; Chiba K; Ishizaki T; Kaneko E
Clin Pharmacol Ther; 1999 Sep; 66(3):265-74. PubMed ID: 10511062
[TBL] [Abstract][Full Text] [Related]
7. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
[TBL] [Abstract][Full Text] [Related]
8. [Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration].
Huang Y; Yang JF; Qi XL; Wang YQ; Wang WZ; Chen B
Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(20):1686-9. PubMed ID: 15569425
[TBL] [Abstract][Full Text] [Related]
9. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.
Shon JH; Yoon YR; Kim KA; Lim YC; Lee KJ; Park JY; Cha IJ; Flockhart DA; Shin JG
Pharmacogenetics; 2002 Mar; 12(2):111-9. PubMed ID: 11875365
[TBL] [Abstract][Full Text] [Related]
10. Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients.
Miura M; Inoue K; Satoh S; Itoh Y; Kagaya H; Tada H; Tanaka Y; Habuchi T; Suzuki T
Clin Drug Investig; 2007; 27(4):251-8. PubMed ID: 17358097
[TBL] [Abstract][Full Text] [Related]
11. Effects of CYP2C19 genetic polymorphisms on atomoxetine pharmacokinetics.
Choi CI; Bae JW; Lee YJ; Lee HI; Jang CG; Lee SY
J Clin Psychopharmacol; 2014 Feb; 34(1):139-42. PubMed ID: 24346747
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.
Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Valente S; Antoniucci D; Abbate R; Gensini GF
Pharmacogenet Genomics; 2007 Dec; 17(12):1057-64. PubMed ID: 18004210
[TBL] [Abstract][Full Text] [Related]
13. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
Schwab M; Klotz U; Hofmann U; Schaeffeler E; Leodolter A; Malfertheiner P; Treiber G
Clin Pharmacol Ther; 2005 Dec; 78(6):627-34. PubMed ID: 16338278
[TBL] [Abstract][Full Text] [Related]
14. CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans.
Gonzalez HM; Romero EM; Peregrina AA; de J Chávez T; Escobar-Islas E; Lozano F; Hoyo-Vadillo C
J Clin Pharmacol; 2003 Nov; 43(11):1211-5. PubMed ID: 14551175
[TBL] [Abstract][Full Text] [Related]
15. Single-dose pharmacokinetics and pharmacodynamics of oral triazolam in relation to cytochrome P4502C19 (CYP2C19) activity.
Yasui N; Otani K; Ohkubo T; Osanai T; Sugawara K; Chiba K; Ishizaki T; Kaneko S
Ther Drug Monit; 1997 Aug; 19(4):371-4. PubMed ID: 9263374
[TBL] [Abstract][Full Text] [Related]
16. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management.
Sapone A; Vaira D; Trespidi S; Perna F; Gatta L; Tampieri A; Ricci C; Cantelli-Forti G; Miglioli M; Biagi GL; Paolini M
Am J Gastroenterol; 2003 May; 98(5):1010-5. PubMed ID: 12809821
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the CYP2C19 polymorphism in a North-eastern Thai population.
Tassaneeyakul W; Tawalee A; Tassaneeyakul W; Kukongviriyapan V; Blaisdell J; Goldstein JA; Gaysornsiri D
Pharmacogenetics; 2002 Apr; 12(3):221-5. PubMed ID: 11927837
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of the cytochrome P450 2C19 genetic polymorphism.
Desta Z; Zhao X; Shin JG; Flockhart DA
Clin Pharmacokinet; 2002; 41(12):913-58. PubMed ID: 12222994
[TBL] [Abstract][Full Text] [Related]
19. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.
Uno T; Sugimoto K; Sugawara K; Tateishi T
Ther Drug Monit; 2008 Jun; 30(3):276-81. PubMed ID: 18520598
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of etizolam are influenced by polymorphic CYP2C19 activity.
Fukasawa T; Yasui-Furukori N; Suzuki A; Inoue Y; Tateishi T; Otani K
Eur J Clin Pharmacol; 2005 Dec; 61(11):791-5. PubMed ID: 16261363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
